Showing 6981-6990 of 8468 results for "".
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe
- AD Pipeline Watch: Rademikibart Maintains Efficacy Out to Week 52https://practicaldermatology.com/news/ad-pipeline-watch-rademikibart-maintains-efficacy-out-to-week-52/2462145/Connect Biopharma’s rademikibart continues to wow in patients with moderate-to-severe atopic dermatitis, according to topline results from the Stage 2 (maintenance period) of its China pivotal trial. Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα
- Skin of Color Society Kicks Off My Best Winter Skin Campaignhttps://practicaldermatology.com/news/skin-of-color-society-kicks-off-my-best-winter-skin-campaign/2462136/The Skin of Color Society (SOCS) has established a national health awareness day known as
- Ankyra Therapeutics and Regeneron to Evaluate ANK-101 in Combination with Cemiplimab in Patients CSCChttps://practicaldermatology.com/news/ankyra-therapeutics-and-regeneron-to-evaluate-ank-101-in-combination-with-cemiplimab-in-patients-cscc/2462132/Ankyra Therapeutics will be working with Regeneron to evaluate ANK-101 in combination with Regeneron’s anti-PD-1 therapy, Libtayo (cemiplimab) in patients with cutaneous squamous cell carcinoma (CSCC) via a new a clinical trial supply agreement. ANK-101 is a novel first-
- Updated AAD Guidelines on AD in Adults Back Use of Biologics, JAK Inhibitorshttps://practicaldermatology.com/news/updated-aad-guidelines-on-ad-in-adults-back-use-of-biologics-jak-inhibitors/2462123/Updated American Academy of Dermatology (AAD) guidelines on systemic treatment of atopic dermatitis (AD) in adults strongly back the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib. “When the last guidelines were published in 2014, only no
- ACR: TREMFYA Improves Pain, Physical Function and Fatigue in PsA Patients Through Six Monthshttps://practicaldermatology.com/news/acr-tremfya-improves-pain-physical-function-and-fatigue-in-psa-patients-through-six-months/2462121/Substantial numbers of people living with treatment-resistant active PsA who used TREMFYA (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months, according to new data from the CorEvitas Psoriatic Arthritis (PsA) and Spo
- National Rosacea Society Awards 2023 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2023-research-grants/2462117/The National Rosacea Society (NRS) has announced that it will contribute funding for one new study, continue funding for two ongoing studies, as part of its grant program to advance rosacea research. "Ongoing research into the pathologic processes of rosacea has ena
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- Study: Gene Expression Test IDs Best Patients for Adjuvant Radiation Therapyhttps://practicaldermatology.com/news/study-gene-expression-test-ids-best-patients-for-adjuvant-radiation-therapy/2462130/New research suggests that a 40-gene expression profile (40-GEP) test can help identify the best patients for adjuvant radiation therapy for cutaneous squamous cell carcinoma (cSCC). The study, whose results were presented at ASDS 2023, consisted of two merged validation cohorts f
- Study: Bakuchiol-containing Skin Care Regimen Improves Skin Barrier Function Without Disrupting the Microbiomehttps://practicaldermatology.com/news/study-bakuchiol-containing-skin-care-regimen-promotes-microbiome-health-in-sensitive-skin/2462104/A Burt’s Bees bakuchiol-containing skin care regimen can help maintain a balanced skin barrier and microbiome in people with sensitive skin, according to research presented at the 2023 Integrative Dermatology Symposium (IDS). For the study, 45 women aged 35 to 70 years with sensit